Reference : Treatment of drug-induced toxic epidermal necrolysis (Lyell’s syndrome) with intravenous...
Scientific journals : Article
Human health sciences : Anesthesia & intensive care
Human health sciences : Dermatology
http://hdl.handle.net/2268/17027
Treatment of drug-induced toxic epidermal necrolysis (Lyell’s syndrome) with intravenous human immunoglobulins
English
Paquet, Philippe mailto [Université de Liège - ULg > > Dermatopathologie >]
Jacob, Emilie mailto [Université de Liège - ULg > Administration de l'enseignement et des étudiants > AEE : Cellule programmes des cours - Diplômes >]
Damas, Pierre mailto [Université de Liège - ULg > > Soins intensifs >]
Pierard, Gérald mailto [Université de Liège - ULg > > Dermatopathologie >]
2001
Burns : Journal of the International Society for Burn Injuries
Elsevier
27
6
652-655
Yes (verified by ORBi)
International
0305-4179
1879-1409
New York
NY
[en] Toxic epidermal necrolysis ; Lyell’s syndrome ; Immunoglobulin ; Apoptosis
[en] Toxic epidermal necrolysis (TEN) is a rare drug-induced life-threatening disease. Currently, the disease is only treated by supportive and antiseptic measures. Quite recently intravenous immunoglobulins (IG) were shown to be a promising TEN treatment. The rationale for their use is based on the fact that keratinocyte apoptosis in TEN involves the CD95 (APO-1/Fas) cell
surface receptor–ligand system. We successfully treated a TEN patient with high dose of intravenous IG. The clinical recovery appeared exceptionally rapid. Immunohistochemistry showed that the IG action probably developed on the CD95 receptor–ligand system at the keratinocytes surface.
Researchers ; Professionals
http://hdl.handle.net/2268/17027

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
63.pdfPublisher postprint288.96 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.